TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nanologica AB ( (SE:NICA) ) has issued an announcement.
Nanologica AB reported an increase in net sales for the second quarter of 2025, despite a continued operating loss. The company received significant orders for its NLAB Saga® product from new customers in China and the US, marking its entry into the North American market. Additionally, Flerie Invest AB increased its ownership in Nanologica, prompting a mandatory bid offer, which the board advised shareholders to reject.
More about Nanologica AB
Nanologica AB operates in the pharmaceutical industry, focusing on the development and commercialization of nanoporous silica for drug delivery and chromatography applications. The company is expanding its market presence with recent orders from new customers in China and the US.
Average Trading Volume: 314,841
Current Market Cap: SEK96.31M
For a thorough assessment of NICA stock, go to TipRanks’ Stock Analysis page.